Paradigm Shifts in Lipid Lowering
EP. 1: Pathophysiology of Hypercholesterolemia and Cardiovascular Disease
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Manesh Patel, MD, discusses the pathophysiology of the relationship between hypercholesterolemia and cardiovascular disease.
EP. 2: Risk Factors for Developing Hyperlipidemia
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Expert panel of cardiologists provide their perspective on the specific population that may be at a risk of developing hyperlipidemia.
EP. 3: Identifying Patients at High Risk for CV Morbidity and Mortality
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.
EP. 4: High Cholesterol Versus Familial Hypercholesterolemia
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.
EP. 5: Aggressive LDL Lowering in High-Risk Patients
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.
EP. 6: Mechanism of Action of Inclisiran in Lipid Lowering
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.
EP. 7: Outcomes and Practical Implications of Newer Agents
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.
EP. 8: EPA in the Prevention of CV Risk
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.
EP. 9: Emerging Use of Inclisiran as Adjunct Therapy in Hyperlipidemia
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.
EP. 10: Phase 3 ORION Trials for Inclisiran
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.
EP. 11: Inclisiran in the Current Treatment Landscape for Lipid Lowering
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.
EP. 12: Challenging Guidelines in a Non-ACS Population
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.
EP. 13: Cost-Effectiveness of Inclisiran for Treating Hyperlipidemia
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.
EP. 14: Statins as the Standard of Care for Patients With Dyslipidemia
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.
EP. 15: Dietary and Lifestyle Modifications in Lipid Management
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Role of dietary and lifestyle modifications as part of lipid management.
EP. 16: Bempedoic Acid for Lipid Lowering
ByLinda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD,Keith C. Ferdinand, MD Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.
EP. 17: Shared Decision Making and Value-Based Care
ByKeith C. Ferdinand, MD,Linda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD Importance of shared decision making and value-based care when making treatment decisions for cardiovascular patients.
EP. 18: Treatment Decisions and its Relation to Patient Accessibility
ByKeith C. Ferdinand, MD,Linda Hemphill, MD,Dean Karalis, MD,Norman Lepor, MD, FACC, FAHA, FSCAI,Manesh Patel, MD Final thoughts from expert KOLs regarding treatment decisions and how they relate to patient accessibility when manage dyslipidemia.
